Correction : Navigating the Landscape of Liquid Biopsy in Colorectal Cancer: Current Insights and Future Directions (International Journal of Molecular Sciences, (2025), 26, 15, (7619), 10.3390/ijms26157619)

In the original publication [1], there was a mistake in Table 5 and the legend for Table 5. The authors have added the following acronym: “GCP: comprehensive genomic profiling”, which was missing in the original version. Adjustments have also been made regarding the following: -CRICKET study: changed from “50%” to “48%”. -VELO trial: updated from “Phase II” to “Retrospective Analysis”. -CAVE-2 GOIM: from “Panitumumab” to “Cetuximab + avelumab vs. cetuximab”; from “Comprehensive genomic profiling to identify resistance alterations” to “Baseline ctDNA CGP (FoundationOne Liquid CDx) in RAS/BRAFV600E-WT, MSS mCRC to guide rechallenge”; from “42% of patients showed resistance mutations; ultra-selection validated” to “41.7% had resistance mutations; 52.7% had actionable alterations (ESCAT); ultra-selection based on ctDNA may guide treatment”. CRICKET study: changed from “50%” to “48%”. VELO trial: updated from “Phase II” to “Retrospective Analysis”. CAVE-2 GOIM: from “Panitumumab” to “Cetuximab + avelumab vs. cetuximab”; from “Comprehensive genomic profiling to identify resistance alterations” to “Baseline ctDNA CGP (FoundationOne Liquid CDx) in RAS/BRAFV600E-WT, MSS mCRC to guide rechallenge”; from “42% of patients showed resistance mutations; ultra-selection validated” to “41.7% had resistance mutations; 52.7% had actionable alterations (ESCAT); ultra-selection based on ctDNA may guide treatment”. The correct legend and table appear below. Overview of liquid biopsy studies in anti-EGFR therapy for metastatic colorectal cancer. EGFRi: epidermal growth factor receptor inhibitors; ctDNA: circulating tumor DNA; RAS-wt: RAS wild-type; PFS: progression-free survival; OS: overall survival; ORR: objective response rate; BRAF: B-Raf Proto-Oncogene, Serine/Threonine Kinase; MAP2K1: Mitogen-Activated Protein Kinase Kinase 1; VEGFi: Vascular Endothelial Growth Factor Inhibitors; PI3K: Phosphoinositide 3-Kinase; MET: Mesenchymal–Epithelial Transition Factor; BRAF/EGFR: B-Raf Proto-Oncogene, Serine/Threonine Kinase/Epidermal Growth Factor Receptor; GCP: comprehensive genomic profiling. In the original publication [1], the number 272 was omitted at the end of paragraph 4.2.1 in relation to the PARERE study. This reference has now been included. There was an error in the original publication [1]. The sentence describing the initial data for the CAVE-2 GOIM study has been corrected due to an error in the previous version. The incorrect sentence in the previous version is as follows: “The CAVE-2 GOIM trial, presented at ASCO GI 2025, employed comprehensive genomic profiling (CGP) via the FoundationOne Liquid CDx platform, identifying acquired RAS or BRAF mutations in 31.4% of patients and resistance alterations in 42%. Notably, patients who were wt for KRAS, NRAS, BRAFV600E, EGFR, ERBB2, MAP2K1, and PIK3CA experienced significantly longer PFS [269]”. A correction has been made to Section 4, “Advanced Disease: Target and Response Evaluation in Metastatic Colorectal Cancer”, subsection 4.2.1, “Anti-EGFR Therapy: Treatment Selection, Resistance Mechanisms, and Rechallenge Strategies”, paragraph 11. “A recent preplanned baseline translational analysis from the randomized phase II CAVE-2 GOIM trial, avelumab plus cetuximab versus cetuximab alone as anti-EGFR rechallenge in refractory ctDNA RAS/BRAFV600E wt mCRC patients, showed that baseline ctDNA CGP (FoundationOne Liquid CDx) identifies acquired RAS/BRAFV600 and non-RAS/BRAFV600 resistance alterations, supporting liquid-biopsy–guided hyper-selection for anti-EGFR rechallenge in refractory RAS/BRAFV600E–wild-type mCRC [269].” In the first sentence of Section 4, “Advanced Disease: Target and Response Evaluation in Metastatic Colorectal Cancer”, subsection 4.2.1, “Anti-EGFR Therapy: Treatment Selection, Resistance Mechanisms, and Rechallenge Strategies”, paragraph 12. the word “Recently” has been corrected to the word “Moreover”. Reference number 269 has been updated to include a recently published study related to CAVE-2 GOIM. Reference number 305 has been corrected to accurately reflect the molecular analyses of the BEACON study, as the previous version contained an error. The authors state that the scientific conclusions are unaffected. This correction was approved by the Academic Editor. The original publication has also been updated.